NYSE · CIK 0000105770 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
WEST PHARMACEUTICAL SERVICES, INC.
WST chart by TradingView
PRICE HISTORY
LIVE · NYSEWST chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $3.1B
- EBITDA
- $0.8B
- FREE CASH FLOW
- $0.5B
- EPS
- $6.79
- GROSS MARGIN
- 35.91%
- ROIC
- 19.08%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
45.3x
+12%29.5x66.9x
⤢
P / SALES (TTM)
7.7x
+105%3.8x12.6x
⤢
P / BOOK
8.6x
+75%4.9x15.3x
⤢
EV / EBITDA (TTM)
29.4x
+47%19.4x45.7x
⤢
EV / REVENUE (TTM)
7.6x
+102%3.8x12.4x
⤢
FCF YIELD (TTM)
1.71%
+0.8pp0.77%2.52%
⤢
DIVIDEND YIELD (TTM)
—
-0.3pp0.31%0.66%
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.9B
+132%⤢
EBITDA (DERIVED)
$0.2B
+207%⤢
NET INCOME
$0.2B
+310%⤢
EPS (DILUTED)
$2.16
+331%⤢
REVENUE GROWTH YOY
13.80%
+4.5pp-6.86%37.25%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
9.26%
+4.0pp-4.33%21.74%
⤢
RETURN ON CAPITAL
20.49%
+8.7pp10.23%36.25%
⤢
RETURN ON EQUITY (TTM)
18.89%
+6.8pp10.22%29.42%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN37.74%
OPERATING MARGIN20.53%
NET MARGIN17.65%
FCF MARGIN9.26%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.1B
+310%⤢
STOCK-BASED COMP
$0.0B
+137%⤢
CAPITAL EXPENDITURE
$0.0B
-11%⤢
SHARES OUTSTANDING
0.07B
-5%⤢
DIVIDEND / SHARE
—
+69%BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.4B
+112%⤢
TOTAL DEBT
$0.2B
-12%⤢
DEBT / EBITDA (TTM)
0.2x
-71%0.2x0.8x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 103.80%INSIDERS 0.64%OTHER / RETAIL 0.00%1,171 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 9.71% | 6.8M | $2.42B | +3.6% |
| Vanguard Capital Management LLC | 6.65% | 4.7M | $1.66B | NEW |
| Vanguard Portfolio Management LLC | 5.82% | 4.1M | $1.45B | NEW |
| State Street Corporation | 4.68% | 3.3M | $1.17B | +1.3% |
| Artisan Partners Limited Partnership | 3.78% | 2.7M | $941.1M | -6.8% |
| T. Rowe Price Investment Management, Inc. | 3.33% | 2.3M | $828.7M | +99.2% |
| Generation Investment Management LLP | 3.19% | 2.2M | $794.5M | +43.7% |
| Bank Of New York Mellon Corporation | 2.90% | 2.0M | $723.7M | -17.1% |
| Geode Capital Management, LLC | 2.72% | 1.9M | $677.1M | +2.3% |
| Morgan Stanley | 2.07% | 1.5M | $516.3M | -4.8% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.